Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level

Cancer Letters

Volumn 290, Issue 2, 2010, Pages 192-203

  Barrajón Catalán, Enrique ^a   Menéndez Gutiérrez, María P ^a   Falco, Alberto ^a   Carrato, Alfredo ^b   Saceda, Miguel ^b   Micol, Vicente ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b Elche University Hospital   (Spain)

Author keywords

Anticancer therapy; Breast cancer cells; Cell lysis; HER2; Immunoliposomes; Melittin; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOLIPOSOME; MELITTIN; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL SELECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; DRUG BINDING SITE; DRUG TARGETING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SEPARATION; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIPOSOMES; MELITTEN; RECEPTOR, ERBB-2;

EID: 77649181585     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.09.010     Document Type: Article

References (53)

1. Sznol M., and Holmlund J. Antigen-specific agents in development. Semin. Oncol. 24 (1997) 173-186
2. Noble C.O., Kirpotin D.B., Hayes M.E., Mamot C., Hong K., Park J.W., Benz C.C., Marks J.D., and Drummond D.C. Development of ligand-targeted liposomes for cancer therapy. Expert Opin. Ther. Targets 8 (2004) 335-353
3. Park J.W., Hong K., Kirpotin D.B., Papahadjopoulos D., and Benz C.C. Immunoliposomes for cancer treatment. Adv. Pharmacol. 40 (1997) 399-435
4. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51 (1999) 691-743
5. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., and Redemann C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88 (1991) 11460-11464
6. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19 (2000) 3159-3167
7. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
8. Press M.F., Cordon-Cardo C., and Slamon D.J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5 (1990) 953-962
9. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl. J. Med. 344 (2001) 783-792
10. Kirpotin D., Park J.W., Hong K., Zalipsky S., Li W.L., Carter P., Benz C.C., and Papahadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36 (1997) 66-75
11. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., and Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8 (2002) 1172-1181
12. Patrzykat A., and Douglas S.E. Antimicrobial peptides: cooperative approaches to protection. Protein Peptide Lett. 12 (2005) 19-25
13. Lohner K., and Blondelle S.E. Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. Comb. Chem. High Throughput Screen. 8 (2005) 241-256
14. Bechinger B. Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin. J. Membrane Biol. 156 (1997) 197-211
15. Allende D., Simon S.A., and McIntosh T.J. Melittin-induced bilayer leakage depends on lipid material properties: evidence for toroidal pores. Biophys. J. 88 (2005) 1828-1837
16. Hoskin D.W., and Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta 1778 (2008) 357-375
17. Son D.J., Lee J.W., Lee Y.H., Song H.S., Lee C.K., and Hong J.T. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. Pharmacol. Ther. 115 (2007) 246-270
18. Raghuraman H., and Chattopadhyay A. Melittin: a membrane-active peptide with diverse functions. Biosci. Rep. 27 (2007) 189-223
19. Holle L., Song W., Holle E., Wei Y., Wagner T., and Yu X. A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. Int. J. Oncol. 22 (2003) 93-98
20. Moon D.O., Park S.Y., Heo M.S., Kim K.C., Park C., Ko W.S., Choi Y.H., and Kim G.Y. Key regulators in bee venom-induced apoptosis are Bcl-2 and caspase-3 in human leukemic U937 cells through downregulation of ERK and Akt. Int. Immunopharmacol. 6 (2006) 1796-1807
21. Sui S.F., Wu H., Guo Y., and Chen K.S. Conformational changes of melittin upon insertion into phospholipid monolayer and vesicle. J. Biochem. 116 (1994) 482-487
22. Lin J.H., and Baumgaertner A. Stability of a melittin pore in a lipid bilayer: a molecular dynamics study. Biophys. J. 78 (2000) 1714-1724
23. Hu H., Chen D., Liu Y., Deng Y., Yang S., Qiao M., Zhao J., and Zhao X. Target ability and therapy efficacy of immunoliposomes using a humanized antihepatoma disulfide-stabilized Fv fragment on tumor cells. J. Pharm. Sci. 95 (2006) 192-199
24. Menendez J.A., Vazquez-Martin A., Colomer R., Brunet J., Carrasco-Pancorbo A., Garcia-Villalba R., Fernandez-Gutierrez A., and Segura-Carretero A. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. BMC Cancer 7 (2007) 80
25. Tanner M., Kapanen A.I., Junttila T., Raheem O., Grenman S., Elo J., Elenius K., and Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol. Cancer. Ther. 3 (2004) 1585-1592
26. Olson F., Hunt C.A., Szoka F.C., Vail W.J., and Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim. Biophys. Acta 557 (1979) 9-23
27. Vemuri S., and Rhodes C.T. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm. Acta Helv. 70 (1995) 95-111
28. Huwyler J., Wu D., and Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA 93 (1996) 14164-14169
29. Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., and Allen T.M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239 (1995) 133-144
30. Dynamic light scattering: an introduction in 30 min, Malvern Instruments technical note (MRK656-01), Malvern Instruments Ltd., 2008. Available from: .
31. Villari V., and Micali N. Light scattering as spectroscopic tool for the study of disperse systems useful in pharmaceutical sciences. J. Pharm. Sci. 97 (2008) 1703-1730
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
33. Fiske C.H., and Subbarow Y. The colorimetric determination of phosphorus. J. Biol. Chem. 66 (1925) 375-400
34. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., and Shepard H.M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer. Immunol. Immunother. 37 (1993) 255-263
35. Lam P.B., Burga L.N., Wu B.P., Hofstatter E.W., Lu K.P., and Wulf G.M. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol. Cancer 7 (2008) 91
36. Cooley S., Burns L.J., Repka T., and Miller J.S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp. Hematol. 27 (1999) 1533-1541
37. Pegram M.D., Lipton A., Hayes D.F., Weber B.L., Baselga J.M., Tripathy D., Baly D., Baughman S.A., Twaddell T., Glaspy J.A., and Slamon D.J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16 (1998) 2659-2671
38. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., Untch M., Rusnak D.W., Spehar G., Mullin R.J., Keith B.R., Gilmer T.M., Berger M., Podratz K.C., and Slamon D.J. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66 (2006) 1630-1639
39. Moulder S.L., Yakes F.M., Muthuswamy S.K., Bianco R., Simpson J.F., and Arteaga C.L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61 (2001) 8887-8895
40. Baselga J., and Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12 Suppl. 1 (2001) S35-S41
41. Sun W.Q., Leopold A.C., Crowe L.M., and Crowe J.H. Stability of dry liposomes in sugar glasses. Biophys. J. 70 (1996) 1769-1776
42. Zuba-Surma E.K., Kucia M., Abdel-Latif A., Lillard Jr. J., and Ratajczak M.Z. The ImageStream system: a key step to a new era in imaging. Folia Histochem. Cytobiol. 45 (2007) 279-290
43. Kikumori T., Kobayashi T., Sawaki M., and Imai T. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res. Treat. 113 (2009) 435-441
44. Kullberg M., Mann K., and Owens J.L. A two-component drug delivery system using Her-2-targeting thermosensitive liposomes. J. Drug. Target 17 (2009) 98-107
45. Utsugi T., Schroit A.J., Connor J., Bucana C.D., and Fidler I.J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51 (1991) 3062-3066
46. Gawronska B., Leuschner C., Enright F.M., and Hansel W. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol. Oncol. 85 (2002) 45-52
47. Hansel W., Enright F., and Leuschner C. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol. Cell. Endocrinol. 260-262 (2006) 183-189
48. 2+ entry and subsequent apoptosis induced by melittin in human MG63 osteosarcoma cells. Life Sci. 80 (2007) 364-369
49. Arora A.S., de Groen P.C., Croall D.E., Emori Y., and Gores G.J. Hepatocellular carcinoma cells resist necrosis during anoxia by preventing phospholipase-mediated calpain activation. J. Cell Physiol. 167 (1996) 434-442
50. Saini S.S., Chopra A.K., and Peterson J.W. Melittin activates endogenous phospholipase D during cytolysis of human monocytic leukemia cells. Toxicon 37 (1999) 1605-1619
51. Yan B., Wang H., Zhuo D., Li F., Kon T., Dewhirst M., and Li C.Y. Apoptotic DNA fragmentation factor maintains chromosome stability in a P53-independent manner. Oncogene 25 (2006) 5370-5376
52. Wyllie A.H. Apoptosis: an overview. Br. Med. Bull. 53 (1997) 451-465
53. Kim H.W., Kwon Y.B., Ham T.W., Roh D.H., Yoon S.Y., Kang S.Y., Yang I.S., Han H.J., Lee H.J., Beitz A.J., and Lee J.H. General pharmacological profiles of bee venom and its water soluble fractions in rodent models. J. Vet. Sci. 5 (2004) 309-318